C-type lectin receptors and RIG-I-like receptors: New points on the oncogenomics map

Cancer Management and Research

Volumn 4, Issue 1, 2012, Pages 39-53

  Kutikhin, Anton G ^a   Yuzhalin, Arseniy E ^a  

^a KEMEROVO STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

C type lectin receptors; Cancer; Genetic variation; Inflammation; RIG I like receptors; Single nucleotide polymorphisms

Indexed keywords

C TYPE LECTIN RECEPTOR; CD205 RECEPTOR; CD206 RECEPTOR; CD207 RECEPTOR; CD209 ANTIGEN; DECTIN 1; DECTIN 2; LANGERIN; LECTIN RECEPTOR; MANNOSE RECEPTOR; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PROTEIN CLEC13B; PROTEIN CLEC13D; PROTEIN CLEC1B; PROTEIN CLEC4A; PROTEIN CLEC4E; PROTEIN CLEC4K; PROTEIN CLEC4L; PROTEIN DEC 205; RETINOIC ACID INDUCIBLE PROTEIN I; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER RISK; CARCINOGENICITY; COLORECTAL CANCER; ESOPHAGUS CANCER; GENETIC ASSOCIATION; GENETIC VARIABILITY; GLIOBLASTOMA; HUMAN; LIVER CANCER; LUNG CANCER; LYMPHOMA; MOUTH CANCER; MULTIPLE MYELOMA; NASOPHARYNX CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER;

EID: 84857777751     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S28983     Document Type: Article

References (51)

1. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 2011;34(5):637-650.
2. Elinav E, Strowig T, Henao-Mejia J, Flavell RA. Regulation of the antimicrobial response by NLR proteins. Immunity. 2011;34(5): 665-679.
3. Osorio F, Reis E, Sousa C. Myeloid C-type lectin receptors in pathogen recognition and host defense. Immunity. 2011;34(5):651-664.
4. Loo YM, Gale M Jr. Immune signaling by RIG-I-like receptors. Immunity. 2011;34(5):680-692.
5. Lamba V, Lamba J, Yasuda K, et al. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther. 2003;307(3):906-922.
6. Tierney MJ, Medcalf RL. Plasminogen activator inhibitor type 2 contains mRNA instability elements within exon 4 of the coding region. Sequence homology to coding region instability determinants in other mRNAs. J Biol Chem. 2001;276(17):13675-13684.
7. Thomas KH, Meyn P, Suttorp N. Single nucleotide polymorphism in 55-flanking region reduces transcription of surfactant protein B gene in H441 cells. Am J Physiol Lung Cell Mol Physiol. 2006;291(3): L386-L390.
8. Zysow BR, Lindahl GE, Wade DP, Knight BL, Lawn RM. C/T polymorphism in the 5iiuntranslated region of the apolipoprotein(a) gene introduces an upstream ATG and reduces in vitro translation. Arterioscler Thromb Vasc Biol. 1995;15(1):58-64.
9. Bell JK, Mullen GE, Leifer CA, Mazzoni A, Davies DR, Segal DM. Leucine-rich repeats and pathogen recognition in toll-like receptors. Trends Immunol. 2003;24(10):528-533.
10. Johnson CM, Lyle EA, Omueti KO, et al. Cutting edge: a common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against leprosy. J Immunol. 2007;178(12): 7520-7524.
11. Chang AH, Parsonnet J. Role of bacteria in oncogenesis. Clin Microbiol Rev. 2010;23(4):837-857.
12. de Martel C, Franceschi S. Infections and cancer: established associations and new hypotheses. Crit Rev Oncol Hematol. 2009;70(3):183-194.
13. Hattori T, Konno S, Hizawa N, et al. Genetic variants in the mannose receptor gene (MRC1) are associated with asthma in two independent populations. Immunogenetics. 2009;61(11-12):731-738.
14. Alter A, de Léséleuc L, Van Thuc N, et al. Genetic and functional analysis of common MRC1 exon 7 polymorphisms in leprosy susceptibility. Hum Genet. 2010;127(3):337-348.
15. Hattori T, Konno S, Takahashi A, et al. Genetic variants in mannose receptor gene (MRC1) confer susceptibility to increased risk of sarcoidosis. BMC Med Genet. 2010;11:151.
16. Xu YF, Liu WL, Dong JQ, et al. Sequencing of DC-SIGN promoter indicates an association between promoter variation and risk of nasopharyngeal carcinoma in cantonese. BMC Med Genet. 2010;11:161.
17. Sakuntabhai A, Turbpaiboon C, Casadémont I, et al. A variant in the CD209 promoter is associated with severity of dengue disease. Nat Genet. 2005;37(5):507-513.
18. Wang L, Chen RF, Liu JW, et al. DC-SIGN (CD209) Promoter-336 A/G polymorphism is associated with dengue hemorrhagic fever and correlated to DC-SIGN expression and immune augmentation. PLoS Negl Trop Dis. 2011;5(1):e934.
19. Barreiro LB, Neyrolles O, Babb CL, et al. Promoter variation in the DC-SIGN-encoding gene CD209 is associated with tuberculosis. PLoS Med. 2006;3(2):e20.
20. Vannberg FO, Chapman SJ, Khor CC, et al. CD209 genetic polymorphism and tuberculosis disease. PLoS One. 2008;3(1):e1388.
21. Selvaraj P, Alagarasu K, Swaminathan S, Harishankar M, Narendran G. CD209 gene polymorphisms in South Indian HIV and HIV-TB patients. Infect Genet Evol. 2009;9(2):256-262.
22. Núñez C, Rueda B, Martínez A, et al. A functional variant in the CD209 promoter is associated with DQ2-negative celiac disease in the Spanish population. World J Gastroenterol. 2006;12(27):4397-4400.
23. Núñez C, Oliver J, Mendoza JL, et al. CD209 in inflammatory bowel disease: a case-control study in the Spanish population. BMC Med Genet. 2007;8:75.
24. Mezger M, Steffens M, Semmler C, et al. Investigation of promoter variations in dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN) (CD209) and their relevance for human cytomegalovirus reactivation and disease after allogeneic stem-cell transplantation. Clin Microbiol Infect. 2008;14(3):228-234.
25. Zheng R, Zhou Y, Qin L, et al. Relationship between polymorphism of DC-SIGN (CD209) gene and the susceptibility to pulmonary tuberculosis in an eastern Chinese population. Hum Immunol. 2011; 72(2):183-186.
26. Koizumi Y, Kageyama S, Fujiyama Y, et al. RANTES-28G delays and DC-SIGN-139C enhances AIDS progression in HIV type 1-infected Japanese hemophiliacs. AIDS Res Hum Retroviruses. 2007; 23(5):713-719.
27. Kashima S, Rodrigues ES, Azevedo R, et al. DC-SIGN (CD209) gene promoter polymorphisms in a Brazilian population and their association with human T-cell lymphotropic virus type 1 infection. J Gen Virol. 2009;90(Pt 4):927-934.
28. Ryan EJ, Dring M, Ryan CM, et al. Variant in CD209 promoter is associated with severity of liver disease in chronic hepatitis C virus infection. Hum Immunol. 2010;71(8):829-832.
29. Chan KY, Xu MS, Ching JC, et al. CD209 (DC-SIGN)-336 A. G promoter polymorphism and severe acute respiratory syndrome in Hong Kong Chinese. Hum Immunol. 2010;71(7):702-707.
30. Chan KY, Xu MS, Ching JC, et al. Association of a single nucleotide polymorphism in the CD209 (DC-SIGN) promoter with SARS severity. Hong Kong Med J. 2010;16(5 Suppl 4):37-42.
31. Plantinga TS, Fransen J, Takahashi N, et al. Functional consequences of DECTIN-1 early stop codon polymorphism Y238X in rheumatoid arthritis. Arthritis Res Ther. 2010;12(1):R26.
32. Cunha C, Di Ianni M, Bozza S, et al. Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient-and donordependent mechanisms of antifungal immunity. Blood. 2010;116(24): 5394-5402.
33. Chai LY, de Boer MG, van der Velden WJ, et al. The Y238X stop codon polymorphism in the human p-glucan receptor Dectin-1 and susceptibility to invasive aspergillosis. J Infect Dis. 2011;203(5):736-743.
34. Plantinga TS, van der Velden WJ, Ferwerda B, et al. Early stop polymorphism in human Dectin-1 is associated with increased candida colonization in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2009;49(5):724-732.
35. Plantinga TS, Hamza OJ, Willment JA, et al. Genetic variation of innate immune genes in HIV-infected african patients with or without oropharyngeal candidiasis. J Acquir Immune Defic Syndr. 2010; 55(1):87-94.
36. Pothlichet J, Burtey A, Kubarenko AV, et al. Study of human RIG-I polymorphisms identifies two variants with an opposite impact on the antiviral immune response. PLoS One. 2009;4(10):e7582.
37. Shigemoto T, Kageyama M, Hirai R, Zheng J, Yoneyama M, Fujita T. Identification of loss of function mutations in human genes encoding RIG-I and MDA5: implications for resistance to type I diabetes. J Biol Chem. 2009;284(20):13348-13354.
38. Ovsyannikova IG, Dhiman N, Haralambieva IH, et al. Rubella vaccineinduced cellular immunity: evidence of associations with polymorphisms in the Toll-like, vitamin A and D receptors, and innate immune response genes. Hum Genet. 2010;127(2):207-221.
39. Ovsyannikova IG, Haralambieva IH, Dhiman N, et al. Polymorphisms in the vitamin A receptor and innate immunity genes influence the antibody response to rubella vaccination. J Infect Dis. 2010;201(2):207-213.
40. Hu J, Nistal-Villán E, Voho A, et al. A common polymorphism in the caspase recruitment domain of RIG-I modifies the innate immune response of human dendritic cells. J Immunol. 2010;185(1):424-432.
41. Shu X, Ji J, Li X, Sundquist J, Sundquist K, Hemminki K. Cancer risk among patients hospitalized for Type 1 diabetes mellitus: a populationbased cohort study in Sweden. Diabet Med. 2010;27(7):791-797.
42. Zendehdel K, Nyrén O, Ostenson CG, Adami HO, Ekbom A, Ye W. Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst. 2003;95(23): 1797-1800.
43. Swerdlow AJ, Laing SP, Qiao Z, et al. Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study. Br J Cancer. 2005;92(11):2070-2075.
44. Hjalgrim H, Frisch M, Ekbom A, Kyvik KO, Melbye M, Green A. Cancer and diabetes-a follow-up study of two population-based cohorts of diabetic patients. J Intern Med. 1997;241(6):471-475.
45. Bahmanyar S, Montgomery SM, Hillert J, Ekbom A, Olsson T. Cancer risk among patients with multiple sclerosis and their parents. Neurology. 2009;72(13):1170-1177.
46. Nielsen NM, Rostgaard K, Rasmussen S, et al. Cancer risk among patients with multiple sclerosis: a population-based register study. Int J Cancer. 2006;118(4):979-984.
47. Sumelahti ML, Pukkala E, Hakama M. Cancer incidence in multiple sclerosis: a 35-year follow-up. Neuroepidemiology. 2004;23(5):224-227.
48. Midgard R, Glattre E, Grønning M, Riise T, Edland A, Nyland H. Multiple sclerosis and cancer in Norway. A retrospective cohort study. Acta Neurol Scand. 1996;93(6):411-415.
49. Fois AF, Wotton CJ, Yeates D, Turner MR, Goldacre MJ. Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson's disease: record linkage studies. J Neurol Neurosurg Psychiatry. 2010;81(2):215-221.
50. Pothlichet J, Niewold TB, Vitour D, Solhonne B, Crow MK, Si-Tahar M. A loss-of-function variant of the antiviral molecule MAVS is associated with a subset of systemic lupus patients. EMBO Mol Med. 2011;3(3): 142-152.
51. Liu X, Jiao Y, Wen X, et al. Possible association of VISA gene polymorphisms with susceptibility to systemic lupus erythematosus in Chinese population. Mol Biol Rep. 2011;38(7):4583-4588.